Linzatin M 1000 Tablet contains Metformin 1000mg + Linagliptin 2.5mg, a dual-action oral antidiabetic therapy for type 2 diabetes. Metformin reduces hepatic glucose production and improves insulin sensitivity, while Linagliptin, a DPP-4 inhibitor, increases incretin levels to stimulate insulin secretion and suppress glucagon.
This tablet is part of the diabetes care segment, offering a convenient combination therapy with higher Metformin dosage for patients requiring robust glycemic control. Its fixed-dose formulation reduces pill burden and ensures better patient adherence.
Linzatin M 1000 Tablet is widely prescribed by endocrinologists, general physicians, hospitals, and clinics, ensuring high demand for PCD pharma franchise and B2B distribution. Its dual mechanism provides consistent glycemic control, encouraging repeat prescriptions and long-term patient satisfaction.
For PCD pharma franchise and B2B partners, Linzatin M 1000 Tablet represents a profitable and high-demand opportunity. Its strong demand across hospitals, clinics, and retail pharmacies makes it ideal for domestic distribution, export, and third-party manufacturing, ensuring sustainable business growth and attractive margins.